Alector (ALEC) Competitors $1.33 +0.03 (+2.31%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.34 +0.01 (+1.13%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. TYRA, UPB, CGEM, OPT, AKBA, PGEN, ANAB, MAZE, TRVI, and SAGEShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Tyra Biosciences (TYRA), Upstream Bio (UPB), Cullinan Therapeutics (CGEM), Opthea (OPT), Akebia Therapeutics (AKBA), Precigen (PGEN), AnaptysBio (ANAB), Maze Therapeutics (MAZE), Trevi Therapeutics (TRVI), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Alector vs. Tyra Biosciences Upstream Bio Cullinan Therapeutics Opthea Akebia Therapeutics Precigen AnaptysBio Maze Therapeutics Trevi Therapeutics Sage Therapeutics Alector (NASDAQ:ALEC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership. Do analysts recommend ALEC or TYRA? Alector currently has a consensus target price of $3.50, indicating a potential upside of 163.16%. Tyra Biosciences has a consensus target price of $30.50, indicating a potential upside of 215.73%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ALEC or TYRA? Alector received 122 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 75.56% of users gave Tyra Biosciences an outperform vote while only 60.94% of users gave Alector an outperform vote. CompanyUnderperformOutperformAlectorOutperform Votes15660.94% Underperform Votes10039.06% Tyra BiosciencesOutperform Votes3475.56% Underperform Votes1124.44% Does the media refer more to ALEC or TYRA? In the previous week, Tyra Biosciences had 3 more articles in the media than Alector. MarketBeat recorded 4 mentions for Tyra Biosciences and 1 mentions for Alector. Tyra Biosciences' average media sentiment score of 0.99 beat Alector's score of 0.66 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Alector Positive Tyra Biosciences Positive Which has more volatility & risk, ALEC or TYRA? Alector has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ALEC or TYRA? 85.8% of Alector shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 9.1% of Alector shares are held by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ALEC or TYRA more profitable? Tyra Biosciences has a net margin of 0.00% compared to Alector's net margin of -257.54%. Tyra Biosciences' return on equity of -24.56% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-257.54% -108.77% -27.03% Tyra Biosciences N/A -24.56%-23.31% Which has higher earnings and valuation, ALEC or TYRA? Tyra Biosciences has lower revenue, but higher earnings than Alector. Tyra Biosciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M1.31-$130.39M-$1.23-1.08Tyra BiosciencesN/AN/A-$69.13M-$1.61-6.00 SummaryTyra Biosciences beats Alector on 12 of the 17 factors compared between the two stocks. Remove Ads Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.78M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-0.7829.2923.1319.03Price / Sales1.31436.17383.8993.17Price / CashN/A168.6838.1634.64Price / Book0.943.956.944.33Net Income-$130.39M-$71.95M$3.20B$247.06M7 Day Performance-1.48%-3.76%-2.33%-0.37%1 Month Performance-18.90%-10.33%2.84%-3.85%1 Year Performance-77.91%-27.15%10.75%1.27% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.8691 of 5 stars$1.33+2.3%$3.50+163.2%-78.1%$131.78M$100.56M-0.78270Gap UpTYRATyra Biosciences2.2376 of 5 stars$10.74-6.6%$30.50+184.0%-40.7%$543.48MN/A-6.6720Upcoming EarningsNews CoverageUPBUpstream BioN/A$9.87+2.7%$56.50+472.4%N/A$529.44M$2.37M0.0038Positive NewsCGEMCullinan Therapeutics2.2088 of 5 stars$9.03+2.7%$32.86+263.9%-53.2%$528.37MN/A-3.1830OPTOpthea0.7079 of 5 stars$3.41+7.1%$12.00+252.4%-12.8%$524.07M$87,666.000.008Analyst DowngradeShort Interest ↑Analyst RevisionNews CoverageGap UpAKBAAkebia Therapeutics3.5918 of 5 stars$2.40+6.2%$6.75+181.3%-13.8%$523.63M$169.88M-10.43430PGENPrecigen3.5938 of 5 stars$1.78-1.1%$7.00+293.3%+13.1%$521.31M$3.96M-3.24190Gap UpANABAnaptysBio3.0142 of 5 stars$16.51-1.3%$35.11+112.7%-12.8%$506.31M$91.28M-2.72100Buyback AnnouncementHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.49+4.5%$25.67+123.4%N/A$503.00M$167.50M0.00121TRVITrevi Therapeutics3.6909 of 5 stars$6.54-3.1%$15.94+143.7%+88.2%$502.70MN/A-14.8620Short Interest ↑High Trading VolumeSAGESage Therapeutics2.9592 of 5 stars$8.02+3.9%$8.81+9.9%-54.5%$493.08M$41.24M-1.22690 Remove Ads Related Companies and Tools Related Companies Tyra Biosciences Alternatives Upstream Bio Alternatives Cullinan Therapeutics Alternatives Opthea Alternatives Akebia Therapeutics Alternatives Precigen Alternatives AnaptysBio Alternatives Maze Therapeutics Alternatives Trevi Therapeutics Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
